Management of cryptogenic stroke

Acta Neurologica Belgica

Volumn 110, Issue 2, 2010, Pages 135-147

  Finsterer, Josef ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Cause of stroke; Cerebral ischemia; Cryptogenic stroke; Paroxysmal atrial fibrillation; Patent foramen ovale; Pathogenesis; Stroke of undetermined cause

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTICOAGULATION; AORTA ATHEROSCLEROSIS; ATHEROMA; BLOOD CHEMISTRY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOGENIC STROKE; DOPPLER ECHOGRAPHY; ELECTROCARDIOGRAM; EMBOLISM; FABRY DISEASE; HEART ANEURYSM; HEART ATRIUM FIBRILLATION; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; REVIEW; STENT; STROKE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE; VASCULAR DISEASE; VEIN THROMBOSIS; AGE; COMPLICATION; ELECTROCARDIOGRAPHY; HEART SEPTUM DEFECT; MEDLINE; PROCEDURES; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; BRAIN ISCHEMIA; ELECTROCARDIOGRAPHY; FORAMEN OVALE, PATENT; HEART ANEURYSM; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MEDLINE; RISK FACTORS; STROKE; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 77955972020     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Guercini F, Acciarresi M, Agnelli G, Paciaroni M. Cryptogenic stroke: time to determine aetiology. J Thromb Haemost. 2008;6:549-554.
2. Timsit S, Breuilly C. Cryptogenic cerebral infarction: from classification to concept. Presse Med 2009; (in press).
3. Tobis MJ, Azarbal B. Does patent foramen ovale promote cryptogenic stroke and migraine headache? Tex Heart Inst J. 2005;32:362-365.
4. Knebel F, Masuhr F, von Hausen W, Walde T, Dreger H, Raab V, Yuerek M, Baumann G, Borges AC. Transesophageal echocardiography in patients with cryptogenic cerebral ischemia. Cardiovasc Ultrasound. 2009;7:15.
5. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382-390.
6. Palomeras E, Fossas P, Cano A, Sanz P. Cryptogenic infarct. A follow-up period of 1 year study. Neurologia. 2009;24:304-308.
7. Elijovich L, Josephson SA, Fung GL, Smith WS. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis. 2009;18:185-189.
8. Kaya D, Yildiz E. Aortic atheromas in stroke subgroups detected by multidetector computed tomographic angiography. Clin Neurol Neurosurg. 2009;111:415-421.
9. Harloff A, Dudler P, Frydrychowicz A, Strecker C, Stroh AL, Geibel A, Weiller C, Hetzel A, Hennig J, Markl M. Reliability of aortic MRI at 3 Tesla in patients with acute cryptogenic stroke. J Neurol Neuro surg Psychiatry. 2008;79:540-546.
10. Wöhrle J. Closure of patent foramen ovale after cryptogenic stroke. Lancet 2006;368:350-352.
11. Carod-Artal FJ, Vilela Nunes S, Portugal D. Thrombophilia and patent foramen ovale in young stroke patients. Neurologia. 2006;21:710-716.
12. Palazzuoli A, Ricci D, Lenzi C, Lenzi J, Palazzuoli V. Transesophageal echocardiography for identifying potential cardiac sources of embolism in patients with stroke. Neurol Sci. 2000;21:195-202.
13. Rigatelli G, Aggio S, Cardaioli P, Braggion G, Giordan M, Dell'avvocata F, Chinaglia M, Rigatelli G, Roncon L, Chen JP. Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism? JACC Cardiovasc Interv. 2009;2: 655-662.
14. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009;40:2349-2355.
15. Spies C, Khandelwal A, Timmemanns I, Kavinsky CJ, Schräder R, Hijazi ZM. Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism . Catheter Cardiovasc Interv. 2008;72:966-970.
16. Force M, Massabuau P, Larrue V. Prevalence of atrial septal abnormalities in older patients with cryptogenic ischemic stroke or transient ischemic attack. Clin Neurol Neurosurg. 2008;110:779-783.
17. Fraticelli A, Gambini C, Iannoni E, Paciaroni E. Impending paradoxical embolism through a patent foramen ovale in an octogenarian with pulmonary embolism: detection by transesophageal echocardiography and successful treatment by anticoagulation. Arch Gerontol Geriatr. 1998;27:41-47.
18. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357: 2262-2268.
19. Casaubon L, McLaughlin P, Webb G, Yeo E, Merker D, Jaigobin C. Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci. 2007;34:74-80.
20. Nedeltchev K, Arnold M, Wahl A, Sturzenegger M, Vella EE, Windecker S, Meier B, Mattle HP. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry. 2002;72:347-350.
21. Rodés-Cabau J, Noël M, Marrero A, Rivest D, Mackey A, Houde C, Bédard E, Larose E, Verreault S, Peticlerc M, Pibarot P, Bogaty P, Bertrand OF. Atherosclerotic burden findings in young cryptogenic stroke patients with and without a patent foramen ovale. Stroke. 2009;40:419-425.
22. Weimar C, Holle DN, Benemann J, Schmid E, Schminke U, Haberl RL, Diener HC, Goertler M. Current Management and risk of recurrent stroke in cerebrovascular Patients with right-to-left cardiac shunt. Cerebrovasc Dis. 2009;28:349-356.
23. Zito C, Dattilo G, Oreto G, Di Bella G, Lamari A, Iudicello R, Trio O, Caracciolo G, Coglitore S, Arrigo F, Carerj S. Patent foramen ovale: comparison among diagnostic strategies in cryptogenic stroke and migraine. Echocardiography 2009;26:495-503.
24. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005; 112:1063-1072.
25. Suslina ZA, Foniakin AV, Chechetkin OA, Glebov MV, Geraskina LA, Nikitin IuM, Kravchenko MA. Paradoxical embolism in patients with ischemic stroke. Klin Med (Mosk). 2008;86:35-39.
26. Nedeltchev K, Wiedmer S, Schwerzmann M, Windecker S, Haefeli T, Meier B, Mattle HP, Arnold M. Sex differences in cryptogenic stroke with patent foramen ovale. Am Heart J. 2008;156:461-465.
27. Johansson MC, Eriksson P, Dellborg M. The significance of patent foramen ovale: a current review of associated conditions and treatment. Int J Cardiol. 2009;134:17-24.
28. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol. 2001;38:613-623.
29. Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr JP, Homma S; Patent Foramen Ovale in Cryptogenic Stroke Study Investigators. Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009;119:2376-2382.
30. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/ American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke.. 2006; 37:577-617.
31. Goel SS, Tuzcu EM, Shishehbor MH, de Oliveira EI, Borek PP, Krasuski RA, Rodriguez LL, Kapadia SR. Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am J Cardiol 2009;103: 124-129.
32. Ozdemir AO, Tamayo A, Munoz C, Dias B, Spence JD. Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism. J Neurol Sci. 2008;275:121-127.
33. Presbitero P, Lanzone AM, Albiero R, Lisignoli V, Zavalloni Parenti D, Gasparini GL, Lodigiani C, Barbaro C, Fappani A, Barberis G, Rossi ML, Pagnotta P. Anatomical patterns of patent foramen ovale (PFO): do they matter for percutaneous closure? Minerva Cardioangiol. 2009;57:275-284.
34. Rigatelli G, Dell'avvocata F, Braggion G, Giordan M, Chinaglia M, Cardaioli P. Persistent venous valves correlate with increased shunt and multiple preceding cryptogenic embolic events in patients with patent foramen ovale: an intracardiac echocardiographic study. Catheter Cardiovasc Interv. 2008;72:973-976.
35. Thaler DE, Saver JL. Cryptogenic stroke and patent foramen ovale. Curr Opin Cardiol. 2008;23:537-544.
36. Homma S, DiTullio MR, Sacco RL, Sciacca RR, Mohr JP; PICSS Investigators. Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke. 2004;35:2145-2149.
37. Belvís R, Tizzano EF, Martí-Fàbregas J, Leta RG, Baena M, Carreras F, Pons-Lladó G, Baiget M, Martí-Vilalta JL. Mutations in the NKX2-5 gene in patients with stroke and patent foramen ovale. Clin Neurol Neurosurg. 2009;111:574-578.
38. Serafini O, Misuraca G, Greco F, Bisignani G, Manes MT, Venneri N. Prevalence of structural abnormalities of the atrial septum and their association with recent ischemic stroke or transient ischemic attack: echocardiographic evaluation in 18631 patients. Ital Heart J Suppl. 2003;4:39-45.
39. von Bardeleben RS, Richter C, Otto J, Himmrich L, Schnabel R, Kampmann C, Rupprecht HJ, Marx J, Hommel G, Münzel T, Horstick G. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm. Int J Cardiol. 2009;134:33-41.
40. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003; 139:753-760.
41. Almekhlafi MA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti DL, Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale: a metaanalysis. Neurology. 2009;73:89-97.
42. Feurer R, Sadikovic S, Esposito L, Schwarze J, Bockelbrink A, Hemmer B, Sander D, Poppert H. Lesion patterns in patients with CS with and without right-to-left-shunt. Eur J Neurol. 2009;(in press).
43. Rajamani K, Chaturvedi S, Jin Z, Homma S, Brey RL, Tilley BC, Sacco RL, Thompson JL, Mohr JP, Levine SR; PICSS-APASS Investigators. Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study. Stroke. 2009;40:2337-2342.
44. Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke. 2007;38:2070-2073.
45. Serena J, Marti-Fàbregas J, Santamarina E, Rodríguez JJ, Perez-Ayuso MJ, Masjuan J, Segura T, Gállego J, Dávalos A; CODICIA, Right-to-Left Shunt in Cryptogenic Stroke Study; Stroke Project of the Cerebrovascular Diseases Study Group, Spanish Society of Neurology. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke. 2008;39:3131-3136.
46. Salmasi AM, Salmasi H, Rawlins S, Baakil M, Dancy M. Atrial Septal Aneurysm and Patent Foramen Ovale Are Less Prevalent in the Indo-Asian Than in the Caucasian or Afro-Caribbean Population. Angiology. 2009;(in press).
47. Bonati LH, Kessel-Schaefer A, Linka AZ, Buser P, Wetzel SG, Radue EW, Lyrer PA, Engelter ST. Diffusion- weighted imaging in stroke attributable to patent foramen ovale: significance of concomitant atrial septum aneurysm. Stroke. 2006;37:2030-2034.
48. Sheikhzadeh A, Ehlermann P. Atheromatous disease of the thoracic aorta and systemic embolism. Clinical picture and therapeutic challenge. Z Kardiol. 2004;93:10-17.
49. Luermans JG, Post MC, Plokker HW, Ten Berg JM, Suttorp MJ. Complications and mid-term outcome after percutaneous patent foramen ovale closure in patients with cryptogenic stroke. Neth Heart J. 2008;16:332-336.
50. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J; Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740-1746.
51. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol. 2003;42:1066-1072.
52. Palmieri V, Tufano A, Carmen Bonito M, Martino S, Sabatella M, Di Minno G, Celentano A. Right-to-left shunt, atrial septal aneurysm and thrombophilia in patients with cryptogenic stroke or TIA vs. those with venous thrombo-embolism. Int J Cardiol. 2008;130:99-102.
53. Freeman WD, Aguilar MI. Stroke prevention in atrial fibrillation and other major cardiac sources of embolism . Neurol Clin. 2008;26:1129-1160.
54. Suissa L, Bertora D, Lachaud S, Mahagne MH. Score for the targeting of atrial fibrillation (STAF): a new approach to the detection of atrial fibrillation in the secondary prevention of ischemic stroke. Stroke. 2009;40:2866-2868.
55. Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Revisiting Libman-Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol. 2009;36:126-130.
56. Amarenco P. Underlying pathology of stroke of unknown cause (cryptogenic stroke). Cerebrovasc Dis. 2009;27(suppl 1):97-103.
57. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
58. Harloff A, Markl M, Frydrychowicz A, Hennig J, Weiller C. Diagnosing stroke aetiologies: morphologic and functional analysis of the aorta and carotid arteries by MRI. Nervenarzt. 2009;80:929-940.
59. Kaps M, Rauh JR, Lieberknecht M, Druschky KF. The aortic arch as an embolism source for cerebral infarcts. Fortschr Neurol Psychiatr. 1996;64:367-374.
60. Terasaki T, Yonehara T, Fujioka S, Hashimoto Y, Uchino M. Two cases of brain infarction associated with dissection of the thoracic aorta. Rinsho Shinkeigaku. 1999;39:619-624.
61. Harloff A, Handke M, Reinhard M, Geibel A, Hetzel A. Therapeutic strategies after examination by transesophageal echocardiography in 503 patients with ischemic stroke. Stroke. 2006;37:859-864.
62. Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Löhr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366: 1794-1796.
63. Fellgiebel A, Keller I, Marin D, Müller MJ, Schermuly I, Yakushev I, Albrecht J, Bellhäuser H, Kinateder M, Beck M, Stoeter P. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology. 2009;72:63-68.
64. Moskau S, Smolka K, Semmler A, Schweichel D, Harbrecht U, Müller J, Pohl C, Klockgether T, Linnebank M. Common genetic coagulation variants are not associated with ischemic stroke in a case control study. Neurol Res 2009; (in press).
65. Weber R, Busch E. Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment. Nervenarzt. 2005;76:193-201.
66. Potaczek DP, Pieculewicz M, Mazur M, Branicka A, Nishiyama C, Okumura K, Podolec P, Undas A. Tissue factor +5466A>G polymorphism predicts plasma TF levels in subjects with cryptogenic ischaemic stroke. Thromb Haemost. 2009;102:173-175.
67. Dodge SM, Hassell K, Anderson CA, Keller J, Groves B, Carroll JD. Antiphospholipid antibodies are common in patients referred for percutaneous patent foramen ovale closure. Catheter Cardiovasc Interv. 2004;61:123-127.
68. Lentini A, Fornengo P, Bosco G, Caprioli M, Destefanis E, Cerrato P. Cryptogenic cerebral infarction in a young patient with very high lipoprotein(a) serum level as the only risk factor. Neurol Sci. 2007;28:42-44.
69. Undas A, Podolec P, Zawilska K, Pieculewicz M, Jedli ski I, Stepie E, Konarska-Kuszewska E, Weglarz P, Duszy ska M, Hanschke E, Przewlocki T, Tracz W. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke. 2009;40:1499-1501.
70. Morris JG, Duffis EJ, Fisher M. Cardiac workup of ischemic stroke: can we improve our diagnostic yield? Stroke. 2009;40:2893-2898.
71. Rus Mansilla C, Mesa Rubio D, Suárez de Lezo Cruz Conde J, Rodríguez Almodovar A, Durán Torralbo C, Delgado Ortega M. Utility of transesophageal echocardiography in young patients with cryptogenic stroke and low cardiovascular risk. Med Clin (Barc). 2008;130:241-245.
72. de Bruijn SF, Agema WR, Lammers GJ, van der Wall EE, Wolterbeek R, Holman ER, Bollen EL, Bax JJ. Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. Stroke. 2006;37:2531-2534.
73. Walpot J, Pasteuning WH, Hoevenaar M, den Braber J, Sorgedrager J, Oostdijk-de Rijke M, van Kooten-Meyer L. Transesophageal echocardiography in patients with cryptogenic stroke: does it alter their management? A 3-year retrospective study in a single non-referral centre. Acta Clin Belg. 2006;61: 243-248.
74. Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, Jarouse J, Brillman J, Murali S, Gupta R. Atrial fibrillation detected by mobile cardiac out - patient telemetry in cryptogenic TIA or stroke. Neurology. 2008;71:1696-1701.
75. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke. A systematic review. Stroke. 2007;38: 2935-2940.
76. Bell C, Kapral M. Use of ambulatory electrocardiography for the detection of paroxysmal atrial fibrillation in patients with stroke. Canadian Task Force on Preventive Health Care. Can J Neurol Sci. 2000; 27:25-31.
77. Wallmann D, Tüller D, Wustmann K, et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients. An opportunity for a new diagnostic strategy. Stroke. 20007;38:2292-2294.
78. Bansil S, Karim H. Detection of atrial fibrillation in patients with acute stroke. J Stroke Cerebrovasc Dis. 2004;13:12-15.
79. Barthélémy JC, Féasson-Gérard S, Garnier P, Gaspoz JM, Da Costa A, Michel D, Roche F. Automatic cardiac event recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann Noninvasive Electrocardiol. 2003;8: 194-199.
80. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke. 2004;35:1647-1651.
81. Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, Fuster V, Fayad ZA. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009; (in press).
82. Indolfi G, Bartolini E, Trapani S, Azzari C, Resti M. Cryptogenic stroke in a boy with atrial septal defect and hyperhomocysteinemia. J Child Neurol. 2008; 23:1070-1071.
83. Rachko M, Safi AM, Yeshou D, Pillai N, Salciccioli L, Stein RA. Cryptogenic ischemic stroke and paradoxical embolism: should a patent foramen ovale be closed? Case report and literature review. Angiology. 2001;52:793-799.
84. McGaw D, Harper R. Patent foramen ovale and cryptogenic cerebral infarction. Intern Med J. 2001;31: 42-47.
85. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P; Warfarin- Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345: 1444-1451.
86. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, for the PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale. Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625-2631.
87. Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I; NYU Atheroma Group. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol. 2002;90:1320-1325.
88. Messé SR, Kasner SE. Is closure recommended for patent foramen ovale and CS? Patent foramen ovale in CS: not to close. Circulation. 2008;118:1999-2004.
89. O'Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC; American Heart Association; American Stroke Association; American College of Cardiology Foundation. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2009;53: 2014-2018.
90. Halperin JL. What can ongoing clinical trials of anticoagulants demonstrate? J Cardiovasc Med (Hagerstown). 2009;10:610-615.
91. Harrer JU, Wessels T, Franke A, Lucas S, Berlit P, Klötzsch C. Stroke recurrence and its prevention in patients with patent foramen ovale. Can J Neurol Sci. 2006;33:39-47.
92. Ford MA, Reeder GS, Lennon RJ, Brown RD, Petty GW, Cabalka AK, Cetta F, Hagler DJ. Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack: the Mayo Clinic experience. JACC Cardiovasc Interv. 2009;2:404-411.
93. Bronzetti G, D'Angelo C, Donti A, Maria Picchio F, Boriani G. Role of atrial fibrillation after trans - catheter closure of patent foramen ovale in patients with or without CS. Int J Cardiol. 2009; (in press).
94. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, Mattle HP, Meier B. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with CRYPTOGENIC STROKE 147 crypto genic stroke. J Am Coll Cardiol. 2004;44: 750-758.
95. van de Wyngaert F, Kefer J, Hermans C, Ovaert C, Pasquet A, Beguin C, Sindic C, Sluysmans T. Absence of recurrent stroke after percutaneous closure of patent foramen ovale despite residual right-to-left cardiac shunt assessed by transcranial Doppler. Arch Cardiovasc Dis. 2008;101:435-441.
96. Gasiavelis N, Grinnemo KH, Lindblom D, Dellgren G. Surgical closure of patent foramen ovale in patients with suspected paradoxical embolism: longterm results. Scand Cardiovasc J. 2004;38:375-379